Solifenacin
- Generic Name
- Solifenacin
- Brand Names
- Vesicare
- Drug Type
- Small Molecule
- Chemical Formula
- C23H26N2O2
- CAS Number
- 242478-37-1
- Unique Ingredient Identifier
- A8910SQJ1U
- Background
Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily.
Solifenacin was granted FDA approval on 19 November 2004.
- Indication
Solifenacin tablets are indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Overactive Bladder Syndrome (OABS)
- Associated Therapies
- -
A Study in Healthy Volunteers Comparing Two Different Liquid Formulations of Solifenacin With Each Other and With the Tablet Formulation
- First Posted Date
- 2011-08-01
- Last Posted Date
- 2011-08-24
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01406158
- Locations
- 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States
A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 640
- Registration Number
- NCT01371994
- Locations
- 🇺🇸
Methodist Hospital Research Institute, Houston, Texas, United States
🇺🇸Virginia Mason Medical Center, Seattle, Washington, United States
🇺🇸Swedish Urology Group, Seattle, Washington, United States
A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder
- First Posted Date
- 2011-04-21
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 1307
- Registration Number
- NCT01340027
- Locations
- 🇫🇷
FR33111, Paris Cedex 13, France
🇸🇰SK42109, Banska Bystrica, Slovakia
🇸🇰SK42106, Piestany, Slovakia
A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment
- First Posted Date
- 2011-03-21
- Last Posted Date
- 2014-07-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 100
- Registration Number
- NCT01318837
Therapy of the Overactive Bladder Syndrome
- First Posted Date
- 2011-03-15
- Last Posted Date
- 2016-05-20
- Lead Sponsor
- Cantonal Hospital, Frauenfeld
- Target Recruit Count
- 66
- Registration Number
- NCT01314781
- Locations
- 🇨🇭
Blasenzentrum, Cantonal Hospital, Frauenfeld, Thurgau, Switzerland
A Clinical Study to Assess the Effect on Pharmacokinetics of Dosing Mirabegron (YM178) and Solifenacin Simultaneously
- Conditions
- Interventions
- First Posted Date
- 2011-02-16
- Last Posted Date
- 2013-07-29
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 41
- Registration Number
- NCT01297192
Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2014-01-23
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 40
- Registration Number
- NCT01215721
- Locations
- 🇺🇸
University of California, Irvine Medical Center, Orange, California, United States
A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person's Mental Ability
- First Posted Date
- 2010-05-19
- Last Posted Date
- 2012-10-15
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 26
- Registration Number
- NCT01126424
A Study to Evaluate Response of Overactive Bladder Symptom Score (OABSS) to Treatment
- Conditions
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2011-01-13
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 55
- Registration Number
- NCT01122563
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
- Conditions
- Interventions
- First Posted Date
- 2010-03-26
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 547
- Registration Number
- NCT01093534
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.